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Abstract 
With the rapid succession of new effective agents for melanoma in the recent years, the paradigm for treatment of 
metastatic melanoma is changing. The success of combining multiple effective agents compared with outcomes of 
monotherapy also brings increasing complexity in the treatment algorithm for various subsets of metastatic mela-
noma patients. We reviewed the recent reports on novel melanoma therapy to shed light on rational decision-making 
in treating these patients.
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Background
Recent rapid succession of breakthroughs in melanoma 
therapy has dramatically changed the treatment para-
digm for metastatic melanoma over the last 5 years. The 
remarkable success of immune checkpoint inhibitors in 
metastatic melanoma treatment has validated immuno-
therapy as a major modality for cancer treatment in addi-
tion to surgery, chemotherapy, and radiation therapy. The 
elucidation of molecular pathways in cancer biology has 
given rise to targeted therapy with dramatic responses in 
select metastatic melanoma patients. The development of 
oncolytic virus in melanoma treatment has brought forth 
the first FDA-approved oncolytic viral therapy for cancer. 
With these exciting breakthroughs in melanoma therapy 
and continuing to emerge novel therapies for melanoma, 
the landscape of therapeutic options for patients with 
advanced stages of melanoma has drastically changed in 
comparison to options available for 30 plus years until 
2011. In 2011, the FDA approved ipilimumab, a cyto-
toxic T-lymphocyte 4 (CTLA-4) inhibitor, based on the 
results of a 3-arm randomized phase III trial comparing 
a gp100 vaccine alone, ipilimumab alone, and the com-
bination of vaccine with ipilimumab [1]. Subsequently, 
vemurafenib, a BRAF inhibitor, was approved in the same 
year for patients with metastatic melanoma harboring 
BRAF mutation [2, 3]. In 2013, the combination of BRAF 
inhibitor, dabrafenib, and MEKinhibitor, trametinib, was 
approved for BRAF mutation positive metastatic mela-
noma patients [4]. Approval of two inhibitors of the pro-
grammed death 1 (PD-1) receptor, pembrolizumab and 
nivolumab, were granted in 2014 [5, 6]. This review will 
attempt to summarize the advancement in novel mela-
noma therapy in the literature from the recent years and 
provide a reference for treatment decision consideration.
Targeted therapy
Mutation in the serine-threonine kinase BRAF was 
observed in close to 50 % of metastatic melanoma lesions, 
mostly of the valine to glutamine substitution in codon 
600 (V600E) [7]. Other less common BRAF mutations 
with lysine (V600K) or arginine (V600R) substitutions 
have also been reported. Vemurafenib and dabrafenib are 
the currently FDA-approved BRAF inhibitors that target 
these mutations for the treatment of melanoma. BRAF 
inhibitors have shown high rates of response (48–59 %) 
in phase II and III trials but with limited duration [2, 3, 
8]. The median progression-free survival (PFS) ranges 
from 5.1 to 6.8  months [8, 9]. The lack of durability of 
response is due to the development of resistance, mainly 
reactivation of the mitogen-activated protein kinase 
(MAPK) pathway. Although reactivation of MAPK path-
way was observed in over two-thirds of BRAF-inhibitor 
progressing tumors, amplification of parallel signaling 
networks such as the PI3K–PTEN–AKT pathway were 
also found [10–12]. Based on preclinical models, com-
bined treatment with BRAF and MEK inhibitors might 
attenuate development of resistance by blocking reac-
tivation of the MAPK pathway induced by single-agent 
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BRAF inhibitors [13, 14]. As a first-line monotherapy, 
treatment with MEK inhibitor trametinib has also shown 
similar response rate (48 %) and PFS (4.8 months) com-
pared with BRAF inhibitors [15].
Combination of BRAF/MEK inhibition with dab-
rafenib (BRAF inhibitor) and trametinib (MEK inhibitor) 
was evaluated in a phase I/II study [4]. The absence of 
drug–drug interaction was confirmed in 8 patients with 
repeated doses of trametinib and a single dose of dab-
rafenib. Escalating doses of dabrafenib (75 and 150  mg 
twice daily [BID]) in combination with trametinib (1, 1.5 
and 2 mg every day [QD]) were evaluated in 77 patients 
to determine toxicity profile and pharmacokinetic activ-
ity. In the phase II expansion study, 162 advanced mela-
noma patients with BRAFV600 mutation and no prior 
BRAF targeted therapy were assigned 1:1:1 to receive 
dabrafenib (150 mg QD) and trametinib (either 1 or 2 mg 
QD) or dabrafenib (150  mg QD) monotherapy. Median 
PFS for those in the combination 150/2 group was 9.4 
versus 5.8  months for patients who received dabrafenib 
monotherapy (hazard ratio [HR] for progression or 
death, 0.39; p  <  0.001). In a subsequent phase III study 
(COMBI-d), 423 previously untreated and unresectable 
stage IIIC or stage IV melanoma patients with BRAF 
V600E or V600K mutation were randomized to receive 
combination of dabrafenib (150 mg BID) and trametinib 
(2 mg QD) or dabrafenib and placebo [16]. With a median 
follow-up of 9  months, median PFS was 9.3  months in 
combination group and 8.8  months in dabrafenib-only 
group (HR 0.75; 95  % Confidence Interval [CI] 0.57–
0.99; p  =  0.03). Similar rates of adverse events (AEs) 
were observed between the two groups. However, the 
rate of cutaneous squamous-cell carcinoma was lower 
in the combination group compared with dabrafenib-
only group (2 versus 9  %). Pyrexia were more common 
(51 versus 28 %) and with more severity (grade 3, 6 ver-
sus 2 %) in the combination group. In a follow-up report, 
the median overall survival (OS) was 25.1 months in the 
combination group versus 18.7 months in the dabrafenib 
only group (HR 0.71, 95 % CI 0.55–0.92; p = 0.0107) [17]. 
The median PFS was 11.0  months in the combination 
group and 8.8 months in the dabrafenib only group (HR 
0.67, 95 % CI 0.53–0.84; p = 0.0004). In a second phase 
III trial, combination of dabrafenib (150  mg BID) and 
trametinib (2 mg QD) were compared with vemurafenib 
(960 mg BID) orally as first-line therapy (COMBI-v) [18]. 
The combination also improved OS, PFS, and overall 
response rates (ORR) compared with vemurafenib alone 
group. The OS rate at 12 months was 72 % in the com-
bination group and 65 % in the vemurafenib group (HR 
0.69; 95  % CI 0.53–0.89; p  =  0.005). Median PFS was 
11.4  months in the combination group and 7.3  months 
in the vemurafenib group (HR 0.56; 95 % CI, 0.46–0.69; 
p < 0.001). ORR rate was 64 % in the combination group 
and 51 % in the vemurafenib group (p < 0.001). Cutane-
ous squamous-cell carcinoma and keratoacanthoma 
occurred in 1 % of patients in the combination group and 
18 % of those in the vemurafenib group. In all three stud-
ies, rates of AEs were similar between the combination 
group and the monotherapy group. However, AEs related 
to reactivation of the MAPK pathway were reduced in 
the combination group compared with BRAF inhibi-
tor monotherapy group. Pyrexia was more common and 
more severe in the combination group.
Combination therapy with BRAF inhibitor vemu-
rafenib and MEK inhibitor cobimetinib were also evalu-
ated in clinical trials with similar ORR, PFS and OS as 
dabrafenib and trametinib combination. In the phase Ib 
BRIM7 trial, patients who progressed on vemurafenib 
(n  =  66) or never received BRAF inhibitor (n  =  63) 
were enrolled and treated on ten dosing regimens with 
vemurafenib 720 or 960 mg BID continuously and cobi-
metinib 60, 80, or 100 mg QD for either 14 days on and 
14  days off, 21  days on and 7  days off, or continuously 
[19]. Dose-limiting toxic effects were observed in four 
patients: grade 3 fatigue for more than 7  days, grade 3 
prolongation of QTc, grade 3 stomatitis and fatigue, and 
arthralgia and myalgia. The maximum tolerated dose was 
established as vemurafenib 960  mg BID in combination 
with cobimetinib 60  mg QD 21  days on and 7  days off. 
Confirmed objective responses were observed in 10 of 66 
patients (15  %) who had recently progressed on vemu-
rafenib, with a median PFS of 2.8  months. Confirmed 
objective responses were noted in 55 of 63 BRAF inhibi-
tor naïve patients (87 %) with median PFS of 13.7 months. 
All 63 patients who had never received a BRAF inhibitor 
had evidence of target lesion reduction after combina-
tion treatment. Recent update to the study was reported 
with additional 11 months of follow up [20]. Median OS 
of 28.5 months in the vemurafenib-naïve and 8.4 months 
in the vemurafenib-progressing patients was reported, 
with 2-year OS rates of 61.1 and 15.1 % respectively. In 
the subsequent phase III coBRIM trial, 495 patients with 
treatment-naïve BRAF V600 mutation–positive mela-
noma were randomized to receive vemurafenib (960 mg 
BID) and cobimetinib (60 mg QD 21 days on and 7 days 
off) (combination group) or vemurafenib and placebo 
(control group) [21]. Median PFS was 9.9 months in the 
combination group and 6.2 months in the control group 
(HR 0.51; 95 % CI 0.39–0.68; p < 0.001). ORR was 68 % 
in the combination group as compared with 45 % in the 
control group (p < 0.001), with 10 % complete response 
(CR) in the combination group and 4 % CR in the control 
group. The combination treatment was associated with 
higher incidence of grade 3 or higher AEs, as compared 
with control (65 versus 59 %). The incidence of secondary 
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cutaneous squamous cell cancer was also decreased in 
the combination group compared with control group (2 
versus 11 %). Recent update with 8 months additional fol-
low up reported a PFS of 12.3 months in the combination 
group compared with 7.3  months for the control group 
(HR 0.58) and ORR of 70 versus 50 %, respectively [22].
Another BRAF and MEK inhibitor combination in 
clinical trial is encorafenib and binimetinib. In a phase 
Ib/II trial patients with advanced BRAFV600 positive 
melanoma were treated with 400, 450 or 600 mg QD of 
encorafenib and 45 mg BID of binimetinib [23]. ORR of 
74.5 % with a median PFS of 11.3 months (95 % CI 7.4–
14.6) were observed in the BRAF inhibitor naïve patients 
(n = 55). A 3-arm phase III trial (COLUMBUS) is ongo-
ing where patients are randomized 1:1:1 to encorafenib 
450  mg QD and binimetinib 45  mg BID, encorafenib 
alone at 300 mg QD, and vemurafenib alone [ClinicalTri-
als.gov identifier: NCT01909453].
Recently, encouraging results were also reported with 
agent that targets NRAS mutant melanomas in an open 
label phase III trial randomizing NRAS-mutant mela-
noma patients with or without prior immunotherapy 2:1 
to binimetinib 45 mg BID (n = 269) or DTIC 1000 mg/
m2 every 3  weeks (n  =  133) [24]. Confirmed ORR and 
disease control rate (DCR) were 15 and 58  % for bini-
metinib group compared with 7 and 25 % for DTIC group 
(p = 0.015 [ORR]; p < 0.001 [DCR]), respectively. Median 
duration of response on binimetinib was 6.9 months.
The studies reviewed above are briefly summarized in 
Table 1.
Checkpoint inhibitors
Pembrolizumab, the first anti–PD-1 antibody to be 
approved by the FDA, is a highly selective, human-
ized monoclonal IgG4-kappa isotype antibody against 
PD-1. The results of the first phase I trial led to the FDA 
approval of pembrolizumab in ipilimumab-refractory 
metastatic melanoma patients in September 2014 [5, 
25]. Patients with advanced melanoma with or without 
prior ipilimumab therapy (n = 135) were enrolled (KEY-
NOTE-001) [25]. Doses of pembrolizumab at either 2 or 
10 mg/kg given every 2 or 3 weeks were tested. ORR of 
31–51 and 81 % 1 year survival were observed. To address 
the utility of pembrolizumab in ipilimumab refractory 
patient population, an expansion cohort of 173 patients 
was enrolled in this phase I study [5]. Patients with 
advanced melanoma whose disease had progressed after 
≥2 ipilimumab doses were randomly assigned to 2  mg/
kg pembrolizumab every 3 weeks (n = 89) or 10 mg/kg 
every 3 weeks (n = 84). ORR was 26 % at both doses. The 
drug was well tolerated at both doses with similar safety 
profile and no drug-related deaths. Majority of patients 
in both doses had reduction of the target lesion size from 
baseline: 59 (73 %) patients in the pembrolizumab 2 mg/
kg group and 52 (68 %) in the 10 mg/kg group. The most 
common drug-related AEs of any grade in the 2  mg/kg 
and 10 mg/kg groups were fatigue (33 versus 37 %), pru-
ritus (26 versus 19 %), and rash (18 versus 18 %). Further 
evaluation of pembrolizumab was conducted comparing 
with investigator-choice chemotherapy in ipilimumab-
refractory patients (KEYNOTE-002) [26]. In a rand-
omized phase 2 trial enrolling patients with progressive 
disease after ≥2 ipilimumab doses 540 patients were ran-
domly assigned (1:1:1) to receive pembrolizumab 2  mg/
kg or 10  mg/kg every 3  weeks or investigator-choice 
chemotherapy (paclitaxel plus carboplatin, paclitaxel, 
carboplatin, dacarbazine, or oral temozolomide). PFS 
was improved in pembrolizumab 2  mg/kg cohort (HR 
0.57, 95 % CI 0.45–0.73; p < 0.0001) and pembrolizumab 
10 mg/kg cohort (0.50, 0.39–0.64; p < 0.0001) compared 
Table 1 Recent targeted therapy study results in melanoma
Study Agent(s) Phase of study Median PFS (months) OS ORR (%)
[4] Dabrafenib + trametinib II 9.4 79 % at 1 year 76
Dabrafenib 5.8 70 % at 1 year 54
[16]
[17]
Dabrafenib + trametinib III 11.0 25.1 months 67
Dabrafenib 8.8 18.7 months 51
[18] Dabrafenib + trametinib III 11.4 72 % at 1 year 64
Vemurafenib 7.3 65 % at 1 year 51
[19]
[20]
Cobimetinib + vemurafenib I/II Vemurafenib refractory: 2.8 8.4 months 15
Vemurafenib naïve: 13.7 28.5 months 87
[21]
[22]
Cobimetinib + vemurafenib III 12.3 81 % at 9 months 70
Vemurafenib 7.3 73 % at 9 months 50
[23] Encorafenib + binimetinib I/II 11.3 NA 74.5
[24] Binimetinib III NA NA 15
DTIC 7
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with chemotherapy group. PFS rates at 6  months were 
34  % in pembrolizumab 2  mg/kg group, 38  % in the 
10  mg/kg group, and 16  % in the chemotherapy group. 
Treatment-related grade 3–4 AEs were less in pembo-
lizumab treatment groups, 11  % for 2  mg/kg group and 
14  % for 10  mg/kg group, compared with 26  % in the 
chemotherapy group. Again noted in the pembrolizumab 
groups, the most common treatment-related grade 3–4 
AE was fatigue (1  % in the 2  mg/kg group and <1  % in 
the 10  mg/kg group, compared with 5  % in the chemo-
therapy group). A follow-up pooled analysis of the 655 
enrolled KEYNOTE-001 patients (135 from a nonran-
domized cohort [n = 87 ipilimumab naive; n = 48 ipili-
mumab treated] and 520 from randomized cohorts 
[n = 226 ipilimumab naive; n = 294 ipilimumab treated]) 
was reported in 2016 [27]. Among the 581 patients with 
measurable disease at baseline, ORR was 33 with 45 % in 
treatment-naive patients. 44  % (90/205) of patients had 
response duration for at least 1 year and 79 % (162/205) 
had response duration for at least 6 months. Median OS 
in the total population was 23 months with a 24-month 
survival rate of 49 %. In treatment-naive patients, median 
OS was 31 months with a 24-month survival rate of 60 %. 
It was further noted that a smaller tumor size at baseline 
was associated with a higher ORR. There was no signifi-
cant difference in antitumor activity among the various 
pembrolizumab doses in randomized cohorts. The study 
results were recently updated to include 3  year overall 
survival data [28]. The 36-month OS rate was 40 % and 
median OS was 23.8  months. Based on the finding of 
significant activity of pembrolizumab in treatment naïve 
patients, a randomized controlled phase III study was 
performed (KEYNOTE 006) enrolling 834 patients with 
advanced melanoma assigned in a 1:1:1 ratio to pem-
brolizumab 10 mg/kg every 2 weeks or every 3 weeks or 
four doses of ipilimumab 3 mg/kg every 3 weeks [29]. The 
estimated 6-month PFS rates were 47.3 % for pembroli-
zumab every 2  weeks, 46.4  % for pembrolizumab every 
3 weeks, and 26.5 % for ipilimumab (HR 0.58; p < 0.001 
for both pembrolizumab regimens versus ipilimumab; 
CIs 0.46–0.72 and 0.47–0.72, respectively). Estimated 
12-month survival rates were 74.1, 68.4, and 58.2  %, 
respectively (HR for pembrolizumab every 2 weeks, 0.63; 
95  % CI 0.47–0.83; p =  0.0005; HR for pembrolizumab 
every 3 weeks, 0.69; 95 % CI 0.52–0.90; p = 0.0036). Sig-
nificant improvement in ORR were observed in both 
pembrolizumab treatment groups (33.7  % for every 
2  weeks and 32.9  % for every 3  weeks) compared with 
ipilimumab group (11.9 %) (p < 0.001 for both compari-
sons). Reduced rates of treatment-related AEs of grade 
3 to 5 severity were noted in the pembrolizumab groups 
(13.3 and 10.1  %) compared with ipilimumab group 
(19.9  %). Based on the fewer toxicities and significantly 
improved OS in the pembrolizumab treatment groups 
compared with ipilimumab group, FDA approved pem-
brolizumab as first-line therapy for metastatic melanoma. 
At a recent update with median follow-up duration of 
22.9 months, the improvement in OS, PFS, and ORR with 
pembrolizumab over ipilimumab held up [30]. Median 
OS was not reached for either pembrolizumab groups 
versus 16.0  months with ipilimumab. The estimated 
24-month OS rates were 55 % for pembrolizumab group 
and 43 % for ipilimumab group.
Nivolumab, a fully human IgG4 monoclonal anti-
body, was the first anti–PD-1 antibody to be evalu-
ated in humans in a phase I trial [31]. Nivolumab at 
doses of 0.1–10 mg/kg produced a 31 % response rate 
in 107 previously treated ipilimumab-naive metastatic 
melanoma patients in a phase I trial [6]. Median dura-
tion of response and median OS were 22  months and 
17.3 months, respectively. Two subsequent randomized 
trials comparing nivolumab with chemotherapy have 
been reported in ipilimumab refractory patients and 
in untreated patients without BRAF mutation [32, 33]. 
Metastatic melanoma patients without BRAF muta-
tion (n  =  418) were randomized to nivolumab 3  mg/
kg every 2  weeks or dacarbazine 1000  mg/m2 every 
3 weeks as first line therapy [32]. Compared with dac-
arbazine as first-line therapy, nivolumab improved 
1-year OS rate, (72.9 versus 42.1  %; HR 0.42; 99.79  % 
CI, 0.25–0.73; p  <  0.001), median PFS (5.1 versus 
2.2 months; HR 0.43; 95 % CI 0.34–0.56; p < 0.001) and 
ORR (40.0 versus 13.9  %; odds ratio 4.06; p  <  0.001). 
Rates of common AEs associated with nivolumab such 
as fatigue, pruritus, and nausea were consistent with 
findings from phase I trials. Grade 3 or 4 AEs occurred 
in 11.7 % of the nivolumab group and 17.6 % of the dac-
arbazine group.
For ipilimumab refractory patients, nivolumab was also 
found to be superior to chemotherapy [33]. Patients who 
progressed after ipilimumab or ipilimumab and a BRAF 
inhibitor if they were BRAF V600 mutation-positive were 
randomized 2:1 to nivolumab 3  mg/kg every 2  weeks 
(n = 272) or investigator choice chemotherapy (n = 133). 
An ORR of 31.7 % was observed in the nivolumab group 
compared with 10.6 % in the chemotherapy group. There 
was no significant difference in response to nivolumab 
in patients with or without previous benefit from anti-
CTLA4 therapy, ORR of 30 and 32.5  %, respectively. 
This dataset has led to the FDA approval of single-agent 
nivolumab in ipilimumab-refractory metastatic mela-
noma patients in December 2014.
The studies reviewed above are briefly summarized in 
Table 2.
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Combination of checkpoint inhibitors
The success of CTLA-4 inhibition and PD-1/PD-L1 
inhibition in the treatment of cancer has lead to greater 
appreciation of the complexity of tumor microenviron-
ment and the various interacting components that may 
present as unique opportunities for manipulation to con-
trol cancer. Conventional activated CD4+ and CD8+ 
T cells expressed CTLA-4 on the surfaces following 
induction [34, 35]. CTLA-4 binds to B7.1 (CD80) and 
B7.2 (CD86) on antigen presenting cells (APCs), where 
it competes with costimulatory receptor CD28. Binding 
of CTLA-4 to CD80/CD86 reduces CD28-dependent 
costimulation. CTLA-4 also mediates direct inhibitory 
effects on the MHC-TCR pathway by impairing TCR 
signaling [36]. Furthermore, CTLA-4 is constitutively 
expressed on CD4+CD25+FOXP3+ regulatory T cells 
and plays a role in their suppressive functions [37–39]. 
Programmed cell death protein-1 (PD-1; also known as 
CD27) is also a coinhibitory CD28-family molecule [35]. 
While CTLA-4 functions in the early phase of naïve T 
cell activation, PD-1 is mainly active in the late phase by 
inducing exhaustion in effector T cells. PD-1 is expressed 
on activated T cells, T regs [40], activated B cells, NK 
cells, and monocytes. It binds to PD-L1 (programmed 
death ligand-1, B7-H1) and PD-L2 (programmed death 
ligand-2, B7-DC) on APCs. PD-1 binding results in 
decreased TCR signaling [36]. Tumor cells utilize the PD-
1-PD-L1/2 pathway to evade immune surveillance [41]. 
The observation that PD-1 inhibition is active in CTLA-4 
inhibitor refractory patients confirms the complemen-
tary effects of dual checkpoint inhibition [5, 33].
In a randomized double-blind 3-arm study, treatment 
naive unresectable stage III or IV melanoma patients 
(n = 945) were randomized in a 1:1:1 ratio to nivolumab 
3 mg/kg every 2 weeks, nivolumab 1 mg/kg every 3 weeks 
plus ipilimumab 3  mg/kg every 3  weeks for four doses 
followed by nivolumab 3 mg/kg every 2 weeks for cycle 
three and beyond, or ipilimumab 3 mg/kg every 3 weeks 
for four doses [42]. The median PFS was 11.5  months 
in the combination group compared with 2.9 months in 
the ipilimumab group (HR 0.42; 99.5  % CI, 0.31–0.57; 
p < 0.001) and 6.9 months in the nivolumab group (HR 
for the comparison with ipilimumab, 0.57; 99.5  % CI, 
0.43–0.76; p  <  0.001). While median PFS was simi-
lar between the combination group and the nivolumab 
group in patients with tumors positive for the PD-1 
ligand (PD-L1) at 14.0  months, median PFS was longer 
with the combination therapy than with nivolumab alone 
in patients with PD-L1–negative tumors (11.2 versus 
5.3 months). The activity of nivolumab-ipilimumab com-
bination was similar in patients with and without BRAF 
mutation. ORR were 43.7  % in the nivolumab group, 
57.6 % in the combination group, and 19.0 % in the ipili-
mumab group. The percentage of CR was higher in the 
combination group (11.5 %) than in either the nivolumab 
group (8.9  %) or the ipilimumab group (2.2  %). More 
treatment related AEs of grade 3 or 4 occurred in the 
combination group (55.0 %) compared with those of the 
nivolumab group (16.3  %) and the ipilimumab group 
(27.3  %). Discontinuation of treatment due to AEs also 
occurred more frequently in the combination group 
(36.4  %) compared with nivolumab group (7.7  %) and 
ipilimumab group (14.8 %). While one study-drug related 
death was reported in the nivolumab group (neutropenia) 
and one in the ipilimumab group (cardiac arrest), none 
was reported in the combination group. The study results 
Table 2 Recent checkpoint inhibitor study results in melanoma
Prior Tx patients with prior treatment for metastatic melanoma included. Yes/No indicates a mixed population of treatment naïve and pre-treated patients
Study Phase of study Prior Tx Agent ORR (%) PFS OS
[25] I Yes/no Pembrolizumab 31–51 >7 months NA
[5] I Yes Pembrolizumab 26 37–45 % at 6 months 58–63 % at 1 year
[26] II Yes Pembrolizumab 21–25 34–38 % at 6 months NA
Chemotherapy 4 16 % at 6 months
[27]
[28]
I/II Yes/no Pembrolizumab 33 35 % at 1 year 23 months
40 % at 3 years
[29]
[30]
III No Pembrolizumab 32.9–33.7 46.4-47.3 % at 6 months 55 % at 2 years
Ipilimumab 11.9 26.5 % at 6 months 43 % at 2 years
[6] I Yes Nivolumab 31 27 % at 2 years 16.8 months
43 % at 2 years
[32] III No Nivolumab 40.0 5.1 months 72.9 % at 1 year
DTIC 13.9 2.2 months 42.1 % at 1 year
[33] III Yes Nivolumab 31.7 48 % at 6 months NA
Chemotherapy 10.6 34 % at 6 months
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were updated after more than18  months of follow-up 
[43]. Median PFS continued to be significantly longer 
for combination group (11.5  months) and nivolumab 
group (6.9  months) compared with ipilimumab group 
(2.9  months) (p  <  0.001). Median duration of response 
for combination group responders has not been reached 
compared with 22.3 months for the nivolumab respond-
ers and 14.4 months for the ipilimumab responders.
The improvement in tumor response with combi-
nation CTLA-4 and PD-1 inhibition compared with 
CTLA-4 inhibition alone was also observed in another 
randomized double-blind trial [44]. Treatment naïve 
metastatic melanoma patients (n  =  142) were ran-
domly assigned in a 2:1 ratio to ipilimumab 3 mg/kg and 
nivolumab 1  mg/kg or placebo once every 3  weeks for 
four doses, followed by nivolumab 3  mg/kg or placebo 
every 2  weeks. Among patients with BRAF wild-type 
tumors, ORR was 61  % in the combination group ver-
sus 11 % in the monotherapy (p < 0.001). There were 16 
patients (22  %) with CR in the combination group and 
none in the monotherapy group. Similar findings were 
also observed among patients with BRAF mutation–
positive tumors with ORR of 52  % for those receiving 
combination therapy and CR rate of 22 %. Similar to the 
observation in the other randomized trial, the combina-
tion therapy is associated with more frequent grade 3 or 
4 drug-related AEs compared with monotherapy group, 
54 versus 24 %. The most common grade 3 or 4 AEs asso-
ciated with the combination therapy were colitis (17 %), 
diarrhea (11 %), and an elevated alanine aminotransferase 
level (11 %). However, there was no significant difference 
in response rates between patients whose pretreatment 
tumors were defined as PD-L1–positive and those whose 
tumors were PD-L1–negative. Despite the significant 
clinical efficacy with combination of nivolumab and ipili-
mumab demonstrated in these initial studies, caution was 
raised for further studies to clarify the various patient 
subsets with optimal upfront therapy [45].
The impressive efficacy with dual CTLA-4 and PD-1 
inhibition was also reported in the KEYNOTE-029 
expansion trial testing pembrolizumab and ipilimumab 
combination [46]. Treatment naïve metastatic mela-
noma patients (n  =  153) received pembrolizumab 
2  mg/kg every 3  weeks plus ipilimumab 1  mg/kg every 
3  weeks for 4 doses followed by pembrolizumab 2  mg/
kg every 3  weeks until intolerable toxicity, progression, 
or 24  months. Grade 3–4 treatment related AEs were 
observed in 41 patients (38  %). ORR by central review 
was 57 % with 10 % CR and 47 % partial responses (PR). 
PFS at 6 months was 70 %.
The studies reviewed above are briefly summarized in 
Table 3.
Oncolytic virus
Another promising novel therapy of melanoma is the 
recently approved genetically modified oncolytic virus 
for intralesional injection of cutaneous, subcutaneous, 
and nodal metastatic melanoma patients who progressed 
after surgery. Oncolytic virus preferentially replicates in 
tumor cells which results in tumor cell lysis. Following 
cell lysis, tumor-associated antigens and danger-asso-
ciated molecules were released to promote anti-tumor 
immune responses as well as release of new viral particles 
for infecting nearby viable tumor cells. In the case of the 
recently approved talimogene laherparepvec (T-VEC), 
anti-tumor immune response following oncolysis is puta-
tively enhanced by viral expression of GM-CSF which 
was inserted into the T-VEC genome. T-VEC is a Her-
pes simplex virus type-1 with several key genetic modi-
fications. Deletion of ICP34.5 gene results in enhanced 
viral replication in cancer cells [47]. Deletion of ICP47 
enhances antigen presentation and maintains cell surface 
MHC-I-antigen expression on infected cancer cells [48, 
49]. Further improving the immunogenicity of T-VEC, 
2 copies of the human GM-CSF gene were incorporated 
into the deleted ICP34.5 genome location [50].
In a phase I study, T-VEC has been to shown to repli-
cate intratumorally and express GM-CSF with acceptable 
safety profile [51]. In phase II study, ORR of 26 % (n = 13) 
was observed in 50 stage IIIc and IV melanoma patients 
Table 3 Recent combination checkpoint inhibitor study results in melanoma
Study Phase of study Prior Tx Agents ORR PFS
[42]
[43]
III No Ipilimumab 19.0 2.9 months
Nivolumab 43.7 6.9 months
Nivolumab + ipilimumab 57.6 11.5 months
[44] III No Nivolumab + ipilimumab 52–61 8.5 months (BRAF mutant)
Not reached (BRAF wildtype)
Ipilimumab 11 2.7 months (BRAF mutant)
4.4 months (BRAF wildtype)
[46] II No Pembrolizumab + ipilimumab 57 70 % at 6 months
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with 8 CRs and 5 PRs [52]. Responses were observed in 
both injected and uninjected lesions, including visceral 
lesions. In a phase III multicenter trial, 436 patients with 
unresectable stage IIIB-IV melanoma patients were rand-
omized at a 2:1 ratio to intralesional T-VEC (n = 295) or 
subcutaneous GM-CSF (n = 141) [53]. Durable response 
rates (DRR; responses lasting 6  months or more) was 
significantly higher in the T-VEC group (16.3  %; 95  % 
CI 12.1–20.5 %) compared with GM-CSF control group 
(2.1 %; 95 % CI 0–4.5 %; odds ratio, 8.9; p = 0.001). ORR 
in the T-VEC arm was higher at 26.4  % compared with 
5.7  % in the control arm. Although there was a trend 
for longer median OS in the T-VEC arm at 23.3 months 
compared with 18.9  months in the control arm, it was 
not significant (p = 0.051). The most common AEs with 
T-VEC were fatigue, chills, and pyrexia. The most com-
mon grade 3 or 4 AE was cellulitis (2.1 %). This dataset 
led to the FDA approval of T-VEC for intratumoral injec-
tion of cutaneous, subcutaneous, and nodal metastatic 
melanoma. To further elucidate the immunologic basis of 
its mechanism of action, a post hoc analysis of the phase 
II study (n = 50) was performed [54]. Reduction of tumor 
burden ≥30  % of uninjected non-visceral lesions was 
observed in 11 of 23 patients (47.8 %) and ≥30 % reduc-
tion in the total burden of visceral lesions was observed 
in 2 of 12 patients (16.7 %).
Multimodal combination therapy
With the promising activity of both RAS-RAF-MAPK 
pathway inhibition and checkpoint inhibition in mela-
noma treatment, combination of both modes of therapy 
has been attempted. BRAF inhibition can have immuno-
sensitization effects through increased antigen presenta-
tion, [55–57]. Antigen-specific T cell recognition [56, 58], 
homing of immune effector cell to the tumors [57, 59, 
60] and improved T cell effector functions [61, 62]. MEK 
inhibition can also have immunosensitizing effect via up-
regulation of tumor antigen expression and presentation 
[55, 63]. Paradoxically, MEK inhibitor can also dampen 
immune effector functions since impaired T cell prolifer-
ation and functions with MEK inhibition have been dem-
onstrated in vitro [55, 64].
However, significant liver toxicity resulting in trial 
termination was observed in the first clinical trial of 
vemurafenib plus ipilimumab [65]. The first cohort 
of six patients received a run-in period of 1  month of 
vemurafenib (960 mg BID) only, followed by ipilimumab 
(3  mg/kg every 3  weeks for four doses) and concurrent 
BID doses of vemurafenib. Grade 3 elevations in ami-
notransferase levels developed in four patients following 
the first infusion of ipilimumab plus vemurafenib. The 
first 4 of 6 patients enrolled in the second cohort received 
a lower dose of vemurafenib (720 mg BID) plus the full 
dose of ipilimumab. Elevations in aminotransferase lev-
els (grade 3 in two patients and grade 2 in one patient) 
developed within 3 weeks after starting ipilimumab. The 
remaining two patients in the second cohort received 
vemurafenib alone.
In a study combining dabrafenib with or without 
trametinib and ipilimumab at doses of dabrafenib 100 mg 
BID, trametinib 1 mg QD and ipilimumab 3 mg/kg every 
3 weeks for 4 doses, grade 3 colitis complicated by perfo-
ration was observed in 2 of 7 advanced melanoma patients 
[66]. The enrollment to the triple combination arm was 
stopped with ongoing enrollment to the dabrafenib and 
ipilimumab combination arm. Another ongoing phase 
I trial is evaluating the combination of an anti-PD-L1 
antibody MEDI4736 (durvolumab) at 10  mg/kg every 
2 weeks plus dabrafenib 150 mg BID and trametinib 2 mg 
QD [67]. Patients were stratified by BRAF mutation sta-
tus into three different cohorts. BRAF-mutant patients 
received the triple combination and BRAF wild-type 
patients received durvolumab plus trametinib or sequen-
tial trametinib then durvolumab. In the BRAF mutant 
cohort, treatment with the triple combination resulted 
in an ORR of 69 %, and DCR of 100 %. In the BRAF WT 
cohorts, ORR and DCR were 21 and 79 %, respectively, in 
the combination group and 13 and 80 %, respectively, in 
the sequential group. There was no significant increase in 
immune related AEs reported to date.
T-VEC and ipilimumab combination was also tested 
in an open-label, multicenter phase Ib study [68]. 
Patients (n  =  19) with unresectable stage IIIB-IVM1c 
melanoma with injectable cutaneous, subcutaneous, or 
nodal lesion and without prior systemic therapy were 
enrolled. Intratumoral T-VEC as administered accord-
ing to approved dosages and schedule. Beginning in 
week 6, ipilimumab (3  mg/kg) was administered every 
3  weeks for four infusions. One patient received one 
dose of T-VEC and withdrew consent. The efficacy analy-
sis included 18 patients. Five patients (26.3  %) reported 
grade 3 or higher treatment-related AEs, with three 
patients (15.8 %) attributable to T-VEC and four patients 
(21.1 %) attributable to ipilimumab. ORR was 50 % with 
four patients having confirmed CR (22 %). Median time 
to response was 5.3  months (range, 2.6–8.1  months). 
DRR was 44  %. Responses were seen in both injected 
and uninjected lesions. Among the 35 injected lesions, 
26 (74 %) regressed ≥50 % and 11 (31 %) regressed com-
pletely. Among the 23 uninjected measurable lesions, 12 
(52 %) regressed ≥50 %, and nine (39 %) regressed com-
pletely. Regression of uninjected non-visceral lesions was 
observed in five of 10 (50 %) measurable visceral lesions 
with ≥50 % regression.
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Promising novel agents under development
Glembatumumab vedotin
The human 560-amino-acid type I glycoprotein NMB 
(gpNMB) is an intracellular transmembrane protein that 
transits the cell surface with homology to pMEL-17, a 
melanocyte specific marker [69, 70]. It is over-expressed 
in melanoma [70]. Glembatumumab vedotin (CDX-011 
or CR011-vcMMAE) was produced by covalently link-
ing a fully human IGG2 monoclonal antibody against 
gpNMB (CR011) to monomethyl auristatin E (MMAE), 
a potent mitotic spindle formation inhibitor [71–73]. It 
is designed to deliver the MMAE payload upon binding 
to gpNMB on the tumor cells and releasing free MMAE 
following lysosomal internalization and proteolytic cleav-
age of the valine–citrulline linker. Cell death ensues after 
microtubule inhibition by the free MMAE. Glembatu-
mumab vedotin was active against melanoma cell lines 
expressing gpNMB in  vitro and in pre-clinical model 
[70, 74]. A phase I/II study was conducted to assess the 
safety and activity of glembatumumab vedotin in patients 
with unresectable stage III or stage IV melanoma [75]. 
Enrolled patients (n  =  117) received glembatumumab 
vedotin at 3 dosing schedules: every 3  weeks (sched-
ule 1, n  =  79), 2 of 3  weeks (schedule 2, n  =  15), and 
weekly (schedule 3, n = 23) at escalating dosages. Grade 
3/4 treatment-related AEs occurring in ≥2 patients 
were rash, neutropenia, fatigue, neuropathy, arthralgia, 
myalgia, and diarrhea. Three treatment-related deaths 
(resulting from pneumococcal sepsis, toxic epidermal 
necrolysis, and renal failure) occurred at doses exceeding 
the MTDs. In the schedule 1 phase II expansion cohort 
(n =  34), there were five patients (15  %) with PR and 8 
(24 %) with stable disease (SD) for 6 months. ORR was 2 
of 6 (33 %) for schedule 2 MTD and 3 of 12 (25 %) for the 
schedule 3 MTD.
Pv‑10
PV-10 is a sterile preparation of 10  % solution of rose 
bengal disodium (RB) in 0.9  % saline for intralesional 
injection into tumors [76]. RB has been used as intra-
venous diagnostic dye for liver function and as topical 
solution for ophthalmic conditions [77, 78]. Following 
intratumor injection, PV-10 accumulates in tumor lys-
osomes resulting in rapid lysis of tumor cells [79]. The 
lysis of tumor cells following PV-10 injection also induces 
tumor-specific T cell–mediated immune response with 
regression of uninjected lesions [80, 81]. In a phase 1 
study, 8 patients with dermal and/or subcutaneous met-
astatic melanoma were enrolled [81]. CR was observed 
in injected and uninjected lesions in 4 of the 8 patients. 
All 8 patients exhibited partial to complete regression 
of the injected lesion. Best overall response rate (BORR) 
at 12 weeks is 55 %. Of the 6 enrolled patients with his-
tory of prior ipilimumab, PD-1 inhibitor, and/or vemu-
rafenib trestments, 4 of 6 exhibited CR of the injected 
and uninjected lesions. In a subsequent multicenter 
phase II study, 62 stage III and IV treatment-refractory 
patients with at least 1 cutaneous or subcutaneous lesion 
were enrolled [82]. Intralesional (IL) injection of PV-10 at 
0.5 ml per cm3 lesion volume was administered into each 
measurable lesion up to 20 study lesions. Treatments 
were repeated at weeks 8, 12, and 16 for new non-target 
lesions or existing target or non-target lesions not exhib-
iting complete response. BORR of target lesions was 51 % 
with 26 % CR and 25 % PR. DCR was achieved in 69 % of 
patients. Median time to response was 1.9 months. The 
median duration of response was 4.0 months. On analysis 
of lesion-specific responses of the 491 target lesions, CR, 
PR and SD were 53, 5, and 12 %, respectively. 26 % of 42 
patients with designated bystander lesions experienced 
complete regression of the uninjected bystander lesions. 
Treatment was well-tolerated with predominantly mild 
to moderate locoregional or injection site-related AEs.
Conclusion
The treatment paradigm for the management of advanced 
metastatic melanoma patients continues to shift with the 
rapid development of effective agents and combination 
therapy. With the many available active anti-melanoma 
agents, the optimal treatment algorithm for various 
subsets of patients, e.g. BRAF mutants, NRAS mutants, 
PD-1 expressing, has yet to be determined. With further 
understanding of key pathway molecules in melanoma 
oncogenesis, elucidation of components of tumor micro-
environment, fine-tuning of drivers in the host-tumor 
immune relationship, and introduction of novel anti-
tumor agents [83, 84], the outcome for metastatic mela-
noma will continue to improve.
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